Extensive studies have been conducted to define the development, conversion, stability, and regulatory mechanisms of CD4 + Foxp3 + T reg cells in homeostasis and a variety of disease models [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . It is well known that T reg cells are recruited into the tumor microenvironment and act as one of the major immunosuppressors dampening spontaneous tumor-associated antigen (TAA)-specific T cell immunity [4] [5] [6] , as well as immunotherapy-induced and active-vaccination-induced antitumor immunity 5, 6 . However, how T reg cells behave in the metabolically abnormal tumor microenvironment remains unknown.
Extensive studies have been conducted to define the development, conversion, stability, and regulatory mechanisms of CD4 + Foxp3 + T reg cells in homeostasis and a variety of disease models [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] . It is well known that T reg cells are recruited into the tumor microenvironment and act as one of the major immunosuppressors dampening spontaneous tumor-associated antigen (TAA)-specific T cell immunity [4] [5] [6] , as well as immunotherapy-induced and active-vaccination-induced antitumor immunity 5, 6 . However, how T reg cells behave in the metabolically abnormal tumor microenvironment remains unknown.
The Warburg effect is an important metabolic feature in many types of cancer 11 . Recent studies indicate that glycolysis regulates T cell activation and effector function 12, 13 . Given that glucose, among other nutrients, is poorly replenished in tumors, it is assumed that T cell glycolytic metabolism is altered as a result of the Warburg effect in the tumor microenvironment [13] [14] [15] [16] . In support of this, poor glycolysis can alter effector memory T cell function in the tumor microenvironment 14, 16 . In addition, oxygen-sensing prolyl-hydroxylase proteins 17 , potassium ions released from necrotic cells 18 , and abnormal zinc metabolism 19 can impair effector T cell function in the tumor microenvironment. These findings underscore the significance of the metabolic regulation of memory T cells in tumors.
The homeostatic balance between T reg cells and T helper cells may be metabolically regulated in mice [20] [21] [22] [23] . However, T reg cells adopt memory and effector phenotypes in the human tumor microenvironment 4, 24 . It is unknown whether T reg cells are subject to glycolytic regulation in tumors. Furthermore, oxidative stress is an additional metabolic feature in the tumor microenvironment. Recent studies have shown that myeloid dendritic cells (DCs) are phenotypically and functionally altered by oxidative stress in the tumor microenvironment 25 . However, it is unknown whether oxidative stress alters T reg cell phenotype and function in tumors.
To address these questions, we examined the phenotypic and functional nature of T reg cells in the tumor microenvironment in human ovarian cancer and in several types of mouse cancer, and investigated the mechanisms and roles of metabolism in shaping the biological behaviors of T reg cells. We observed that T reg cells were highly apoptotic in the tumor microenvironment, and that apoptotic T reg cells achieved superior suppressor function via an oxidative-stress-associated mechanism. Furthermore, we found that oxidative stress, rather than glycolysis, was the metabolic mechanism that controlled tumor T reg cell functional behavior and tempered the therapeutic efficacy of immune checkpoint therapy.
RESULTS

High T reg cell apoptosis in the tumor microenvironment
A previous study showed that T reg cells are recruited into the human tumor microenvironment and inhibit TAA-specific T cell immunity 4 . However, it is unknown how T reg cells behave in the metabolically abnormal tumor microenvironment. To investigate this, we used polychromatic flow cytometry analysis (Supplementary Fig. 1a ) to analyze cell proliferation and apoptosis in primary Foxp3 + T reg cells and conventional Foxp3 − CD4 + T cells in human ovarian cancer tissues. We found that T reg cells expressed higher levels of the cell cycle protein Ki67 than conventional T cells did in the human ovarian cancer microenvironment (Supplementary Fig. 1b ). In addition, flow cytometry analyses showed that T reg cells underwent substantial apoptosis compared with Foxp3 − conventional T cells in primary and metastatic ovarian cancer tissues, as determined on the basis of cleaved caspase-3 expression (Fig. 1) . Immunofluorescence staining demonstrated the colocalization of Foxp3 and cleaved caspase-3 in ovarian cancer tissues ( Fig. 1c and Supplementary Fig. 1c) . We quantified proapoptotic and antiapoptotic gene transcripts in human ovarian-cancer-infiltrating T reg cells and conventional T cells. T reg cells expressed high levels of proapoptotic gene transcripts ( Fig. 1d ) and low levels of antiapoptotic gene transcripts ( Fig. 1e) compared with conventional T cells in the same human ovarian cancers. We obtained similar results in mice with ID8 ovarian cancer, MC38 colon cancer, and B16 melanoma (Fig. 1f,g ). Furthermore, using gene set enrichment analysis, we found enriched expression of apoptotic genes in infiltrating T reg cells in mouse B16 melanoma ( Fig. 1h and Supplementary Tables 1 and 2) in the GEO database (GSE55705) 26 . In mouse T reg cells cultured with MC38 tumor media, we detected increased expression of proapoptotic genes ( Supplementary Fig. 1d ) and decreased expression of antiapoptotic genes ( Supplementary  Fig. 1e ). Thus, the data indicate that T reg cells are highly apoptotic in the tumor microenvironment.
Apoptotic T reg cells mediate superior immunosuppression
Foxp3 controls T reg cell development and functional integrity 1, 2 . Live T reg cells inhibit TAA-specific T cell activation 4, 6, 27 . It is unknown whether apoptotic T reg cells are functionally suppressive. To test this, we isolated infiltrating T reg cells from human ovarian cancer samples, induced their apoptosis with anti-Fas monoclonal antibody (mAb) (Supplementary Fig. 2a) , and examined their suppressor activity. Apoptotic T reg cells inhibited the expression of interferon-γ (IFN-γ) and tumor necrosis factor (TNF) in CD4 + and CD8 + T cells (Fig. 2a) . When we compared the suppressor activities of live and apoptotic infiltrating T reg cells and apoptotic conventional T cells in human ovarian cancer, we found that apoptotic T reg cells were more efficient than live T reg cells at inhibiting T cell IL-2 production (Fig. 2b) . Thus, human-cancer-associated apoptotic T reg cells are potent immune suppressors.
Next, we carried out similar experiments with T reg cells from healthy mice and tumor-bearing mice. As expected, in the in vitro T cell suppressive assay, live T reg cells from healthy mice inhibited T cell cytokine production ( Supplementary Fig. 2b,c) . We induced T reg cell apoptosis with irradiation, serum starvation, fluorouracil, and antiFas mAb. Similar to what we observed in human apoptotic T reg cells (Fig. 2b) , regardless of how T reg cell apoptosis was induced, mouse apoptotic T reg cells were superior at suppressing the expression of T cell TNF and IL-2 compared with identical amounts of normal live T reg cells (Supplementary Fig. 2b,c) . We further compared the suppressor activities of live and apoptotic mouse MC38-tumor-infiltrating T reg cells. Again, apoptotic mouse tumor-infiltrating T reg cells were more potent suppressors than live T reg cells (Fig. 2c) . Furthermore, mouse apoptotic tumor-infiltrating T reg cells, rather than apoptotic tumor-infiltrating conventional T cells, strongly inhibited T cell IL-2 production (Fig. 2d) . Thus, mouse tumor-associated apoptotic T reg cells are powerful immune suppressors.
In addition to in vitro and ex vivo suppressor activity, we studied whether apoptotic T reg cells suppress tumor immunity in vivo, using three systems: (i) spontaneous tumor immunity, (ii) tumor immunity induced by PD-L1-checkpoint blockade, (iii) and adoptive TAAspecific T-cell-transfusion-mediated tumor immunity. In the first model, we treated mice carrying MC38 cancer cells with apoptotic T reg cells. We found that tumor volumes were larger in mice that received apoptotic T reg cells compared with those in control mice (Fig. 2e) . Then, we examined the potential effect of apoptotic T reg cells on anti-PD-L1 therapy in this model. PD-L1 blockade reduced tumor growth (Fig. 2e) and enhanced the expression of effector T cell cytokines in tumor-draining lymph nodes (Fig. 2f) and tumor tissue (Fig. 2g) . However, apoptotic T reg cells abolished these antitumor effects mediated by anti-PD-L1 ( Fig. 2e-g ). Thus, apoptotic T reg cells inhibit spontaneous and checkpoint-blockade-induced antitumor immunity.
Finally, we explored the role of apoptotic T reg cells in two adoptive TAA-specific T cell transfer models. We transfused MHC class Irestricted (ovalbumin (OVA)-specific; OT-I) T cell receptor-transgenic T cells into ID8-OVA-bearing (otherwise wild-type) mice and then treated the mice with apoptotic T reg cells and live T reg cells. Both apoptotic T reg cells and live T reg cells promoted tumor growth (Supplementary Fig. 2d ) and inhibited effector T cell cytokine expression ( Supplementary Fig. 2e,f) . However, apoptotic T reg cells demonstrated superior suppressor activity compared with that of live T reg cells (Supplementary Fig. 2d-f ). In addition, we transferred T cell receptor-transgenic CD8 + T cells that specifically recognized the melanoma antigen PMEL into B16-F10-bearing Rag2 −/− mice. We treated the mice with apoptotic T reg cells and anti-PD-L1 mAb (Supplementary Fig. 2g ). Again, we found that apoptotic T reg cells suppressed PMEL-specific T cell immunity and disabled the antitumor effect of PD-L1 blockade, as shown by increased tumor growth (Fig. 2h) , shortened mouse survival (Fig. 2i) , and reduced numbers of IFN-γ + TNF + polyfunctional effector T cells (Fig. 2j,k) . Thus, apoptotic T reg cells were superior suppressors in multiple in vitro and in vivo models.
Apoptotic T reg cells make suppressive nonprotein factor(s) Next, we studied the cellular and molecular mechanisms by which apoptotic T reg cells suppress T cell activation. Myeloid cells, including macrophages, can process apoptotic cells and may mediate immunosuppression in the tumor microenvironment 28, 29 . To explore whether apoptotic T reg cell-mediated immunosuppression depends on macrophages, we tested the effect of apoptotic T reg cells on tumor immune response with macrophage depletion in an MC38 model. As expected, the addition of apoptotic T reg cells and the depletion of macrophages promoted and inhibited tumor growth, respectively (Fig. 3a) . Accordingly, polyfunctional effector T cell cytokine expression was suppressed after the addition of apoptotic T reg cells and enhanced after macrophage depletion (Fig. 3b,c) . Apoptotic T reg cells remained immunosuppressive after macrophage depletion (Fig. 3a-c) . These observations suggest that macrophages are dispensable for apoptotic T reg cell-mediated immunosuppression in this system.
On the molecular level, live T reg cells express Foxp3 and can mediate immunosuppression via multiple modes of action 5, 30, 31 . Immunoblotting showed high levels of immunosuppression-associated membrane molecules, including PD-L1, PD-1, CTLA-4, CD39, (Fig. 3d) . PD-1 and PD-L1 blockade with specific antibodies had no effect on the suppressive properties of apoptotic T reg cells (Fig. 3e) . Apoptotic T reg cells from PD-L1-deficient (Cd274 −/− ) (Fig. 3f) , PD-1-deficient (Pdcd1 −/− ) (Fig. 3g) , and wild-type mice suppressed T cell IL-2 expression to similar degrees (Fig. 3f,g ). CTLA-4 blockade did not change the suppressive activity of apoptotic T reg cells (Supplementary Fig. 3a-c) . In addition to membrane proteins, it is possible that, similarly to live T reg cells, apoptotic T reg cells may release soluble factors including cytokines to mediate T cell suppression. To test this possibility, we collected apoptotic T reg cell-derived supernatants via ultracentrifugation. The supernatants from apoptotic T reg cells inhibited T cell IL-2 expression in a dose-dependent manner (Supplementary Fig. 3d ). However, neutralization of the immunosuppressive cytokine TGF-β ( Supplementary Fig. 3e-g ), IL-35 subunit EBI3 ( Supplementary  Fig. 3h-j) , and IL-10 ( Supplementary Fig. 3k-m) with blocking antibodies did not rescue this suppression. Thus, apoptotic T reg cells release unknown soluble immunosuppressive factor(s), and TGF-β, IL-35, and IL-10 are not involved in apoptotic T reg cell-mediated T cell suppression.
To identify the soluble suppressive factor(s), we divided the apoptotic T reg cell supernatants into two fractions with a 3-kDa molecularweight-cutoff filter. We observed that the fraction above 3 kDa did not suppress T cell IL-2 production, whereas the fraction below 3 kDa did (Fig. 3h) . This molecular weight is consistent with the observations that PD-L1, PD-1, CTLA-4, IL-10, TGF-β, and IL-35 were not involved in the suppressive function of apoptotic T reg cells ( Fig. 3e-g and Supplementary Fig. 3 ). Supernatants from apoptotic T reg cells remained immunosuppressive after treatment with proteinase K (Fig. 3i) or trypsin (Fig. 3j) . However, incubation with dextran-coated charcoal resulted in a loss of immunosuppression (Fig. 3k) . The data suggest that the soluble immunosuppressive factors may be small molecules, rather than proteins or large peptides. 
A r t i c l e s
Apoptotic T reg cells mediate suppression via the A 2A pathway We attempted to define the molecular nature of apoptotic T reg cellderived suppressive supernatants. Live mouse T reg cells express CD39
and CD73 and can convert ATP to adenosine 32 . Live human cancerinfiltrating T reg cells express CD39 and CD73 and inhibit effector T cells through an adenosinergic pathway 33 . We noticed that mouse The effect of the removal of small lipid-like factors on immunosuppression mediated by apoptotic T reg cell supernatants. Apoptotic T reg cell supernatants were mixed with charcoaltreated dextran to remove small lipid-like molecules and were subsequently used for immunosuppression assays. T cell IL-2 was detected on dayapoptotic T reg cells expressed CD39 and CD73 (Fig. 3d) and released a nonprotein small immunosuppressive molecule (or molecules) (Fig.  3h-k and Supplementary Fig. 3 ). Thus, we hypothesized that CD39 and CD73 in apoptotic T reg cells remain enzymatically active and could mediate adenosine production, and that the nonprotein small immunosuppressive molecule might be adenosine. To test this hypothesis, we induced apoptosis in mouse T reg cells with anti-Fas mAb and kinetically measured adenosine in the supernatants. A colorimetric assay detected high amounts of adenosine at 6 h in the apoptotic T reg cell supernatants, but not in live T reg cell medium (Fig. 4a) . Mass spectrometry ( Supplementary Fig. 4a,b) detected a kinetic increase in adenosine levels in apoptotic T reg cell supernatants ( Supplementary  Fig. 4b,c) . The amounts of adenosine also peaked at hour 6 of T reg cell apoptosis (Supplementary Fig. 4c ). Then, we examined the potential suppressive role of adenosine in apoptotic T reg cell supernatants. The addition of exogenous adenosine to mouse T cell cultures led to reduced production of TNF and IL-2 (Fig. 4b,c) . A 2A is a receptor for adenosine in T cells 34 and mediates IL-2 suppression in particular 35 . We observed that the A 2A inhibitor ZM241385 abolished T cell effector cytokine suppression mediated by apoptotic T reg cell supernatants (Fig. 4d,e) . We extended these mouse studies to human ovarian cancer. Again, the supernatants of human ovarian-cancer-infiltrating apoptotic T reg cells inhibited T cell activation. The effect was abrogated by ZM241385 (Fig. 4f,g ). Thus, apoptotic T reg cells mediate immunosuppression via adenosine and the A 2A pathway.
Apoptotic T reg cells release ATP and metabolize it to adenosine Next, we explored how apoptotic T reg cells produce a large amount of adenosine in the absence of exogenous ATP. Gene set enrichment analysis demonstrated that mouse B16-melanoma-infiltrating T reg cells showed active expression of genes associated with purine and pyrimidine metabolism (GSE55705) 26 ( Supplementary Fig. 5a,b) , suggesting high energy metabolism. We hypothesized that apoptotic T reg cells generate, release, and consequently metabolize to adenosine high levels of ATP via apoptotic-cell-associated CD39 and CD73, and ultimately suppress T cell activation via adenosine in the tumor. To test this hypothesis, we induced apoptosis in mouse T reg cells and conventional T cells by anti-Fas treatment (Fig. 5a) , serum starvation (Fig. 5b) , or irradiation (Fig. 5c) . After the induction of apoptosis, T reg cells, but not conventional T cells, released a large amount of ATP (Fig. 5a,b) , possibly owing to the higher ATP content in T reg cells (Supplementary Fig. 5c ). Apoptotic cells can release small molecules via pannexin-1-dependent channels 36 . We found that treatment with pannexin-1 inhibitor (probenecid or carbenoxolone) prevented apoptotic T reg cells from releasing ATP into supernatants (Supplementary Fig. 5d ). Thus, apoptotic T reg cells release ATP via pannexin-1-dependent channels. The amount of ATP released from apoptotic T reg cells peaked between 0.5 and 2 h and decreased to baseline at 6-8 h after apoptosis (Fig. 5a) . This suggests that ATP may be metabolized and converted into adenosine. In line with this, the measured amounts of adenosine inversely correlated with those of ATP and peaked at 6 h after apoptosis in supernatants from apoptotic T reg cells (Fig. 5d) . To determine the ability of apoptotic T reg cells to generate adenosine, we incubated apoptotic T reg cells in medium containing exogenous ADP or ATP. We detected higher amounts of adenosine in culture medium containing apoptotic T reg cells than in the control samples (Fig. 5e) . We collected the supernatants from these experiments and filtered them with a 3-kDa-cutoff filter. Again, these supernatants mediated potent suppression in T cell cytokines (Fig. 5f) . The data suggest that apoptotic T reg cells can convert ADP and ATP to adenosine.
Apoptotic T reg cells express CD39 and CD73 (Fig. 3d) . To directly determine whether CD39 and CD73 are functional in apoptotic T reg cells, we treated apoptotic T reg cells with a CD39 inhibitor, ARL67156, and a CD73 inhibitor, AMP-CP. As expected, ARL67156, but not AMP-CP, prevented ATP degradation (Fig. 5g) . Furthermore, CD39 and CD73 inhibitors rescued IL-2 expression that was inhibited by apoptotic T reg cells (Fig. 5h) . To genetically validate our observation, we tested the suppressive activity of apoptotic T reg cells from CD73-deficient (Nt5e −/− ) mice. Live Nt5e −/− and wild-type T reg cells contained similar amounts of intracellular ATP ( Supplementary  Fig. 5e ). Nt5e −/− and wild-type apoptotic T reg cells released similar amounts of ATP into the medium (Supplementary Fig. 5f ). However, Nt5e −/− apoptotic T reg cells generated less adenosine ( Supplementary  Fig. 5g ) and were less immunosuppressive than wild-type apoptotic T reg cells (Fig. 5i,j) . Next, we treated MC38-tumor-bearing mice with apoptotic Nt5e −/− T cells and apoptotic wild-type T reg cells. We found that tumor volumes were larger in mice that received apoptotic wildtype T reg cells than in those administered apoptotic Nt5e −/− T reg cells (Fig. 5k) , which indicated that apoptotic Nt5e −/− T reg cells were less suppressive than apoptotic Nt5e +/+ T reg cells. In addition, we tested whether ARL67156 (Fig. 5l) and ZM241385 (Fig. 5m) affect apoptotic T reg cell-mediated immunosuppression in MC38-tumor-bearing mice with or without PD-L1 blockade. As shown by changes in tumor volume, the two inhibitors partially subverted the immunosuppressive effect of apoptotic T reg cells and additionally improved the therapeutic outcome of PD-L1 blockade (Fig. 5l,m) . Together, our data suggest that apoptotic T reg cells release high levels of ATP and metabolize it to adenosine via the CD39 and CD73 axis, and suppress T cells through interaction with adenosine and A 2A receptors.
Oxidative stress induces T reg cell apoptosis in tumors Finally, we explored why T reg cells undergo apoptosis in the tumor microenvironment. Effector T cells are affected by glycolytic metabolism in the tumor microenvironment 13, 14, 16 . To explore whether tumor T reg cell apoptosis can be attributed to poor glycolysis, we treated normal T reg cells and conventional T cells with or without glucose and the hexokinase inhibitor 2-deoxy-d-glucose. Glucose restriction and 2-deoxy-d-glucose treatment induced apoptosis in conventional T cells (Supplementary Fig. 6a ), but not in T reg cells (Supplementary Fig. 6b ). Oxidative stress disrupts DC function in ovarian cancer 25 . Thus, we tested whether oxidative stress induces T reg cell apoptosis via reactive oxygen species (ROS) in the tumor microenvironment. To this end, we treated human T reg cells with ovarian cancer ascites. We found that treatment with ovarian cancer ascites and hydrogen peroxide (H 2 O 2 ) induced potent apoptosis in T reg cells, but not in conventional T cells (Fig. 6a and Supplementary Fig. 6c ). T reg cell apoptosis was reversed by treatment with the ROS scavenger N-acetyl-cysteine (Fig. 6a) . Ovarian cancer ascites (Fig. 6b,c) and H 2 O 2 treatment (Fig. 6d,e) led to higher expression of proapoptotic genes (Fig. 6b,d ) and lower expression of antiapoptotic genes (Fig. 6c,e) in T reg cells compared with controls. Furthermore, we detected high concentrations of the major ROS component superoxide in ovarian cancer ascites (Supplementary Fig. 6d ). Ovariancancer-infiltrating T reg cells showed high mitochondrial activity S u lf o r a p h a n e S u lf o r a p h a n e S u lf o r a p h a n e 
compared with that in conventional T cells (Supplementary Fig. 6e ) and produced higher amounts of intracellular ROS ( Supplementary  Fig. 6f) . Thus, T reg cells are relatively more sensitive to oxidative stress in the tumor microenvironment than conventional T cells are, and undergo potent apoptosis.
Next, we wondered why T reg cells are more vulnerable to oxidative stress. The cellular antioxidant system is largely regulated by the transcription factor NRF2 (Nfe2l2) and its associated genes 37, 38 . We quantified the expression of Nfe2l2 and NRF2-associated gene transcripts including Gclm, Gclc, Hmox1, Nqo1, and Ggct in normal T reg cells and conventional T cells. The levels of the majority of these antioxidant gene transcripts were lower in mouse (Fig. 6f)  and human (Supplementary Fig. 6g ) T reg cells than in conventional T cells. Immunoblotting showed lower amounts of NRF2, GLCM, and heme oxygenase (HO-1) proteins in mouse (Fig. 6g) and human  (Supplementary Fig. 6h ) T reg cells than in conventional T cells. Concentrations of intracellular ROS were higher in T reg cells than in conventional T cells (Fig. 6h) . Next, we tested the influence of the NRF2 inducers diethylmaleate and sulforaphane on T reg cell apoptosis in the presence of ovarian cancer ascites. Both NRF2 inducers reduced T reg cell apoptosis compared with that in the control (Fig. 6i) . Furthermore, we treated MC38-tumor-bearing mice with sulforaphane. We found that treatment with sulforaphane reduced T reg cell apoptosis (Fig. 6j) , increased effector T cell cytokine expression (Fig. 6k) , and inhibited tumor growth (Fig. 6l) compared with that observed in the control. Taken together, these data indicate that oxidative stress results in apoptosis of T reg cells via ROS in the tumor microenvironment, which in turn increases their suppressive action.
DISCUSSION
T reg cells are recruited into the tumor microenvironment. It is thought that live, but not apoptotic, T reg cells mediate immune suppression 1, 2, [4] [5] [6] . In this work, we studied T reg cells in human ovarian cancer and in several mouse tumors. We found that T reg cells underwent potent apoptosis in human and mouse tumor microenvironments. To our surprise, apoptotic T reg cells were more efficient than live T reg cells at suppressing T cell activation in vitro and in vivo. More important, we demonstrated that the therapeutic efficacy of PD-L1 blockade was abolished by apoptotic T reg cells in tumor-bearing mouse models. The majority of cancer patients remain unresponsive to therapies based on PD-L1 and PD-1 signaling blockade 39 , and we wondered whether this clinical unresponsiveness (or therapeutic resistance) is associated with high degrees of T reg cell apoptosis in the tumor microenvironment. Furthermore, the targeting of T reg cells is considered a potential therapeutic strategy for cancer treatment. However, clinical trials with T reg cell depletion have not been translated into therapeutic efficacy in people with cancer [40] [41] [42] [43] . This raises the possibility that therapeutic induction of T reg cell apoptosis may sustain and/or amplify, rather than disable, T reg -cell-mediated immunosuppression.
PD-L1, CTLA-4, TGF-β, IL-10, and IL-35 are well-defined immunosuppressive components for live T reg cells [1] [2] [3] [4] [5] [6] . Our biochemical analysis and in vivo functional studies demonstrated that these molecules are not involved in the suppressor activity of apoptotic T reg cells. Live T reg cells express the ectoenzymes CD39 and CD73 and can convert extracellular ATP to adenosine, and in turn mediate immunosuppression via adenosine and the A 2A receptor signaling pathway 32 . We observed that apoptotic T reg cells release a large amount of ATP and efficiently convert ATP into immunosuppressive adenosine via CD39 and CD73 in vitro and in vivo. Therefore, it can be assumed that CD39 and CD73 remain enzymatically active in apoptotic T reg cells. Furthermore, apoptotic T reg cells released a large amount of ATP into the extracellular space via pannexin-1 channels. In line with our observation, mouse apoptotic thymocytes release low-molecularmass compounds via pannexin-1 channels 36 . Thus, apoptotic T reg cells can self-supply and release ATP, and convert it to adenosine in the local environment. We propose a novel immune-evasion mechanism: tumor-infiltrating T reg cells inadvertently die to mediate, sustain, and amplify powerful suppression in the tumor microenvironment.
It has been reported that Foxp3 is a proapoptotic factor for T reg cells in mouse thymus, unless some surviving factors such as γ-chain cytokines are present 44 . We have explored the potential molecular mechanism of T reg cell apoptosis in the tumor microenvironment. Several metabolic checkpoint molecules, including AMPK, mTORC1 (refs. 20,21) , and HIF-1α (refs. 22,23) , may physiologically regulate T reg cell function and the balance between T reg cells and effector T cells in mouse models. However, how T reg cells (particularly human tumor T reg cells) behave in the metabolically abnormal tumor microenvironment remains unknown. Glycolysis profoundly alters effector T cell phenotype and function in the tumor microenvironment [14] [15] [16] . We observed that T reg cells were not as sensitive as effector memory T cells to glycolytic restriction. Instead, we found that T reg cells were vulnerable to oxidative stress in the tumor microenvironment. Our data show that free oxygen species target mitochondria and induce apoptosis in T reg cells, consequently triggering the suppressive cascade of T reg cells in the tumor microenvironment. Thus, our current study complements recent reports on the metabolic control of memory T cells [14] [15] [16] and DCs 25 and extends to T reg cells in human and mouse tumor microenvironments.
In summary, apoptotic T reg cell-mediated immunosuppression may be a major mode of action for T reg cells in cancer and serve as a potential mechanism for checkpoint-blockade resistance. Furthermore, T reg cell apoptosis triggered by oxidative stress is a novel tumor immune-evasion mechanism in the tumor microenvironment, and targeting tumor metabolism is a potential therapeutic strategy for cancer treatment.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper.
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ONLINE METHODS
Ovarian cancer patients, cancer tissues, ascites, and cells. People diagnosed with high-grade serous ovarian carcinomas were recruited for this study, and informed consent was obtained from all participants. The use of human subjects for this study was approved by the University of Michigan Institutional Review Board. We used clinical samples from people who had received no prior anticancer therapies. Fresh tumor tissues and tumor ascites were processed into single-cell suspensions for phenotype and functional studies. Tumor ascites were centrifuged, and cell-free fractions were frozen at −80 °C.
Cell transfection. ID8 cells were transfected with plasmid pCI-neo-mOVA (Addgene plasmid #25099) 45 . Lipofectamine 2000 (Invitrogen) was used for delivery according to the vendor's instructions. The cells were selected with geneticin (Invitrogen), and ovalbumin expression was confirmed by flow cytometry and used for in vivo mouse experiments. For the PMEL-specific mouse model, T cell transfer was accomplished by a single intravenous injection of 10 6 PMEL-specific CD8 + T cells. Donor CD8 + T cells were collected from spleens and lymph nodes of B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J mice and expanded with plate-bound anti-CD3 and soluble anti-CD28 in the presence of recombinant mouse IL-2. Expanded T cells were transferred to mice bearing B16-F10 tumors. Animals were treated as described in Supplementary Figure 2g .
For the OVA-specific model, ID8-OVA-Luc tumor cells were inoculated into B6.SJL-Ptprc a Pepc b /BoyJ mice, which are congenic B6 animals that express CD45.1 antigen. After 7 d, the mice received 10 6 OVA-specific CD45.2 + CD8 + T cells i.p. Animals were treated as described in Supplementary Figure 2d -f. 10 min after the injection of 150 mg/kg body mass d-luciferin (Promega), the bioluminescence of luciferase-expressing tumors was assessed with the IVIS 200 Spectrum imaging system (PerkinElmer).
Treatments with anti-PD-L1 or isotype control antibody (both from Bio X Cell) were done between days 7 and 20 (20 mg/kg i.p.).
Macrophages were depleted with clodronate liposome (Liposoma). Liposomes containing clodronate or control liposomes were injected into mice on days 4, 6, 8, and 10 (200 µl i.p.).
All tumor cell lines used in the experiments were routinely tested for mycoplasma contamination by PCR assay. Randomization of animals was not used in experiments. No blinding was done.
Cell culture and biochemical reagents. RPMI 1640 medium supplemented with 10% FBS (Invitrogen) was used for the majority of the experiments. For cultures without glucose, the cells were treated with RPMI 1640 medium without glucose (Sigma-Aldrich) and charcoal-treated FBS (Invitrogen). Probenecid, carbenoxolone, diethylmaleate, l-sulforaphane, N-acetyl-cysteine, H 2 O 2 , ZM241385, AMP-CP, ARL67165, EHNA, ADP, ATP, and adenosine were obtained from Sigma-Aldrich. Cell lines were obtained from the US National Institutes of Health or ATCC. All cell lines were routinely tested for mycoplasma contamination.
Isolation and culture of T reg cells and conventional T cells.
Single-cell suspensions were prepared from mouse and human tissues including tumor tissues, tumor ascites, and tumor-draining lymph nodes as previously reported [46] [47] [48] [49] . Mouse Foxp3 + GFP + T reg cells were enriched and sorted from spleen and lymph nodes and/or were generated in the presence of IL-2 (10 ng/ml) and TGF-β (10 ng/ml). Human T cells were isolated from healthy donor buffy coats (Carter BloodCare) and purified directly with RosetteSep human T cell enrichment kits (StemCell Technologies). T reg cells from human tumors were isolated with a commercially available T reg cell isolation kit (StemCell) and confirmed by Foxp3 staining.
Induction of T reg cell apoptosis. T reg cells and conventional T cells (5 × 10 6 cells/ml) were incubated with anti-Fas mAb (10 µg/ml; clone Jo-1; eBioscience) for 15-30 min, washed, and suspended for further experiments. Apoptotic T reg cells were also induced by 70-Gy irradiation and cultured serum-free for 24 h and with 5-fluorouracil for 24 h as indicated. For adenosine measurement, erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA), an inhibitor of adenosine deaminase, was used to prevent adenosine degradation over time.
Apoptotic T reg cell-derived supernatants. Apoptotic T reg cell suspensions were centrifuged at 500g for 5 min, 18,000g for 1 h, and 12,000g overnight.
Immunosuppression assay. CD4 + Foxp3 − responder T cells were cocultured with live T reg cells or apoptotic T reg cells or with apoptotic T reg cell-derived supernatants in 96-well round-bottom plates at a ratio of 1:2 in the presence of anti-CD3 (2.5 µg/mL) and irradiated antigen-presenting cells. In some experiments, anti-PD-L1 (eBioscience), anti-PD-1 (eBioscience), anti-TGF-β (R&D), anti-CTLA-4 (BD), anti-IL-10 (eBioscience), and anti-EBI3 (Millipore) blocking antibodies were added into the culture at a final concentration of 10 µg/ml. Cells and culture supernatants were collected for cytokine quantification by flow cytometry analysis and ELISA.
Depletion of proteins and small molecules from T reg cell supernatants. To remove proteins from apoptotic or control T reg cell supernatants, we applied proteinase K or trypsin treatment for 1 h at 37 °C. Next, we inactivated enzymes by boiling samples for 5 min and removed precipitates by centrifugation at 10,000g for 10 min at 4 °C. For the removal of small molecules including lipids, hormones, and nucleotides, media were treated with dextran-coated charcoal (DCC). Briefly, 0.5% (m/v) DCC suspension was mixed with the supernatants at a volume ratio of 5:1 and incubated at room temperature for 20 min. Next, DCC was removed by centrifugation at 7,000g, 30 min, 4 °C. The supernatants were collected for further experiments.
Small-molecule assays. For the ATP assay, pellets of T reg cells and conventional T cells were directly suspended in 1 M perchloric acid and used for ATP assays or stored at −80 °C for further testing. Media were deproteinized with 4 M perchloric acid for further use. A colorimetric ATP measurement kit (Pierce) was used according to the manufacturer's instructions. To measure adenosine, we used adenosine deaminase (Sigma Aldrich) to transform adenosine to xanthine in HClO 4 -deproteinized media, and then we measured xanthine by colorimetric assay (BioVision).
Adenosine was also detected by liquid chromatography coupled with tandem mass spectrometry. Cell culture medium was collected and analyzed freshly in an LC-triple quadrupole mass spectrometer (Agilent 6490 series) with a jet stream electrospray ionization source (Agilent). Chromatography was carried out on a Phenomenex Luna NH2 column (1 × 150 mm) and Agilent 1290 series liquid chromatograph. Mobile phase A was 5 mM ammonium acetate in LC-MS-grade water, pH adjusted to 9.9 with ammonium hydroxide. Mobile phase B was acetonitrile. 200 µl of extraction solvent was added to 200 µl of medium and vertexed briefly. A series of calibration standards (adenosine: 0, 0.01, 0.03, 0.1, 0.3, 1, and 5 µg/ml) were prepared along with the samples. The following transitions were used to identify and quantify adenosine: m/z 266.1 → m/z 134.1. Data were processed by MassHunter workstation software, version B.06. Experiments were performed with biological replicates. Each data point was acquired from cells harvested from different animals.
ELISA. T cell culture supernatants were collected at the time points indicated in the relevant figures. T cell effector cytokines were detected with ELISA kits (R&D).
Real-time PCR. Total RNA was isolated from Trizol-lysed (Invitrogen) samples according to the manufacturer's instructions. A reverse-transcriptase reaction was performed with oligo-dT primers and AMV polymerase (Invitrogen). Real-time PCR reactions were carried out with the Fast-SYBR kit (Applied Biosystems) and the primers listed in Supplementary Table 3. Flow cytometry. Antibodies were from BD Biosciences, eBioscience, or Invitrogen. For human cells, we used anti-CD45 (clone HI30), anti-CD3 (SK7), anti-CD4 (RPA-T4), anti-cCASP3 (9H19L2), anti-Foxp3 (PCH101), anti-TNF (MAb11), anti-IL-2 (MQ1-17H12), and anti-IFN-γ (4S.B3). Mouse cells were stained with anti-CD45 (30-F11) , anti-CD45.1 (A20), anti-CD45.2 (104), anti-CD3 (500A2), anti-CD4 (RM4-5), anti-CD8 (53-6.7), anti-cCASP3 (9H19L2), anti-Foxp3 (FJK-16s), anti-TNF (MP6-XT22), anti-IL-2 (JES6-5H4), and anti-IFN-γ (XMG1.2). For surface staining, the cells were incubated with antibodies for 20 min, washed, and fixed in Fix/Perm solution (BD Biosciences). After being washed with Perm/Wash buffer (BD Biosciences), the cells were stained intracellularly for 30 min, washed, and fixed in 4% formaldehyde (Sigma Aldrich). In the case of apoptosis detection in cell culture, the cells were stained with human recombinant annexin V (BD Biosciences) followed by 7-ADD. In the case of tissue samples, the cells were stained for viability with blue fluorescent fixable dye (Life Technologies) followed by annexin V and Foxp3. All samples were read on an LSR II cytometer (BD) and analyzed with FACS DIVA software v. 8.0 (BD Biosciences).
Immunofluorescence staining. Tumor tissues were fixed in 10% formalin and embedded in paraffin for immunofluorescence staining. Multiplexed fluorescence staining was done with the OpalTM 4-plex staining system (PerkinElmer). Tissue sections were stained with anti-CD3 (clone PS1, mouse IgG2a; Novocastra/Leica), anti-cleaved caspase-3 (rabbit polyclonal IgG; Cell Signaling), and anti-Foxp3 (clone 259D, mouse IgG1; BioLegend). The secondary antibodies used were goat anti-mouse IgG2-α conjugated with Alexa Fluor 488 or goat anti-rabbit IgG (H+L) conjugated with Alexa Fluor 568. Staining slides were analyzed with the Mantra Quantitative Pathology Workstation (PerkinElmer).
Immunoblotting. After centrifugation cells were dissolved in cell lysis buffer (50 mm Tris-HCl, pH 7.4, 1% Triton X-100, 0.2% sodium deoxycholate, 0.2% SDS, 1 mM sodium EDTA) supplemented with protease inhibitors (5 µg/ml leupeptin, 5 µg/ml aprotinin, and 1 mM phenylmethylsulfonyl fluoride) and protein concentrations were determined with Bio-Rad protein assay reagent. The lysates were boiled for 5 min in Laemmli sample buffer (50 mm 
